68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

Effect of 68Ga-NY104 and 18F-FDG PET/CT Guided Radiation Therapy Combined with Systemic Treatment in Patients with Clear Cell Renal Cell Carcinoma.

Radiation therapy (RT) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccRCC). Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastatic/recurrent ccRCC. CAIX is a highly sensitive and specific biomarker expressed on ccRCC and in previous studies the investigators have shown excellent diagnostic efficacy of 68Ga-NY104, a CAIX-targeted PET tracer, in patients with metastatic ccRCC. In this study, the investigators aim to investigate the effect of 68Ga-NY104, and 18F-FDG PET/CT guided RT combining standard systemic therapy in patients with metastatic ccRCC.

Inclusion Criteria:

• Age ≥ 18 years old
• Histologically or cytologically confirmed clear cell renal cell carcinoma
• Eligible for radiation therapy: no more than 10 lesions in total
• Expected survival: over 3 months
• ECOG: 0 or 1
• Sufficient organ function
• Written informed consent

Exclusion Criteria:

• Brain metastasis/carcinomatous meningitis
• Other malignant tumors that are not controlled within 5 years, except for non-metastatic low-risk prostate cancer.
• Pregnant or breastfeeding.
• Active infection.